Patents Assigned to GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
  • Pyridinone dicarboxamide for use as bromodomain inhibitors
    Patent number: 10428026
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: October 1, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Stephen John Atkinson, Helen Elizabeth Aylott, Anthony William James Cooper, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Pyridinone dicarboxamide for use as bromodomain inhibitors
    Patent number: 10370356
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: August 6, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, David House, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Preparation and use of crystalline beta-D-nicotinamide riboside
    Patent number: 10316054
    Abstract: Provided herein are crystalline beta-D-nicotinamide riboside chloride compositions and methods of preparation and use thereof. Also provided are related pharmaceutical compositions and methods of use thereof. The crystalline beta-D-nicotinamide riboside chloride compositions may be used to treat a disease or disorder that would benefit from increased NAD levels including a mitochondrial disease or disorder, insulin resistance, a metabolic syndrome, diabetes, obesity, or for increasing insulin sensitivity in a subject.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: June 11, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Bruce G. Szczepankiewicz, Karsten Koppetsch, Robert B. Perni
  • Combination long acting compositions and methods for Hepatitis C
    Patent number: 10308937
    Abstract: The present Invention relates to pharmaceutical compositions useful in the treatment or prevention or cure of viral infections, such as HCV infections, and diseases associated with such infections.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: June 4, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Zhi Hong, Martin R. Leivers
  • Tricyclic benzoxaborole compounds and uses thereof
    Patent number: 10308668
    Abstract: Compounds of Formula II, wherein X is selected from chloro, fluoro, bromo and iodo, R1 and R2 are each independently selected from H, —CH3, —CH2CH3, —CH2CH2CH3, or —CH(CH3)2; compositions containing them, their use in therapy, including their use as anti-mycobacterial agents, for example in the treatment of a mycobacterial infection in a mammal, and methods for the preparation of such compounds, are provided.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: June 4, 2019
    Assignees: GlaxoSmithKline Intellectual Property (No. 2) Limited, Anacor Pharmaceuticals, Inc.
    Inventors: Michael Richard Kevin Alley, Vincent Hernandez, Jacob J. Plattner, Xianfeng Li, David Barros-Aguirre, Ilaria Giordano
  • PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS
    Publication number: 20190119248
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: April 5, 2017
    Publication date: April 25, 2019
    Applicant: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Stephen John ATKINSON, Emmanuel Hubert DEMONT, Lee Andrew HARRISON, Etienne LEVERNIER, Alexander G. PRESTON, Jonathan Thomas SEAL, Ian David WALL, Robert J. WATSON, James Michael WOOLVEN
  • Pyrrolo[3,2-D]pyrimidine derivatives as inducers of human interferon
    Patent number: 10202386
    Abstract: Compounds of formula (I) and salts thereof: wherein R1 is hydrogen, methyl or —(CH2)2OR3, R2 is methyl or —(CH2)2OR4, or R1 and R2, together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl wherein the 6-membered heterocyclyl is optionally substituted by two hydroxy substituents; R3 and R4 are each independently hydrogen or methyl; and n is an integer having a value of 5 or 6, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment or prevention of various disorders, for example the treatment or prevention of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: February 12, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Keith Biggadike, Aurelie Cecile Champigny, Diane Mary Coe, Daniel Terence Tape, Stephen Allan Smith
  • Chemical compounds
    Patent number: 10196353
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: February 5, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No 2) Limited
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla
  • Long acting pharmaceutical compositions
    Patent number: 10092523
    Abstract: The present invention relates to long acting pharmaceutical compositions or pharmaceutically acceptable salts thereof, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: October 9, 2018
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventor: Brian Alvin Johns
  • METHODS OF TREATING CANCER
    Publication number: 20180280470
    Abstract: Methods of treating cancers comprising FGFR1 gene amplification, FGFR1 overexpression, FGFR3 overexpression, FGFR3 amplification, FGF2 overexpression, and/or FGF2 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent. In some embodiments, methods of treating cancers comprising administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one chemotherapeutic agent are provided.
    Type: Application
    Filed: January 3, 2018
    Publication date: October 4, 2018
    Applicants: Five Prime Therapeutics, Inc., GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Julie Hambleton, Maureen Bleam, Maurice P. DeYoung, Geraldine Ferron-Brady, Rakesh Kumar, Lone Ottesen
  • Substituted bridged urea analogs as sirtuin modulators
    Patent number: 10072011
    Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: September 11, 2018
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: James Lamond Ellis, Karen Anderson Evans, Ryan Michael Fox, William Henry Miller, Mark Andrew Seefeld
  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 10064854
    Abstract: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: September 4, 2018
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Neil W. Johnson, Jiri Kasparec
  • Tetrahydroquinoline derivatives as bromodomain inhibitors
    Patent number: 10059699
    Abstract: The present invention relates to specific novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy as bromodomain inhibitors.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: August 28, 2018
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Stephen John Atkinson, David Jonathan Hirst, Philip G. Humphreys, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
    Patent number: 10034881
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: July 31, 2018
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • Crystalline solid state form of the benzene sulphonic acid salt of 2-[(4S)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide
    Patent number: 9975901
    Abstract: The present invention relates to a salt form of a benzodiazepine derivative, in particular crystalline solid state forms, to pharmaceutical compositions comprising the same and to its use in therapy.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: May 22, 2018
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Gossett Augustus Campbell, Asa Elisabeth Gladwin
  • Crystalline forms
    Patent number: 9902694
    Abstract: This invention relates to crystalline forms of (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile, a modulator of the androgen receptor, and methods for the use in treatment.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: February 27, 2018
    Assignee: GlaxoSmithKline Intellectual Property (No 2) Limited
    Inventors: Istvan Kaldor, Dalin Tang
  • TRICYCLIC BENZOXABOROLE COMPOUNDS AND USES THEREOF
    Publication number: 20180044355
    Abstract: Compounds of Formula II, wherein X is selected from chloro, fluoro, bromo and iodo, R1 and R2 are each independently selected from H, —CH3, —CH2CH3, —CH2CH2CH3, or —CH(CH3)2; compositions containing them, their use in therapy, including their use as anti-mycobacterial agents, for example in the treatment of a mycobacterial infection in a mammal, and methods for the preparation of such compounds, are provided.
    Type: Application
    Filed: October 24, 2017
    Publication date: February 15, 2018
    Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED, ANACOR PHARMACEUTICALS INC.
    Inventors: M. R. K. (DICKON) ALLEY, VINCENT S. HERNANDEZ, JACOB PLATTNER, XIANFENG LI, DAVID BARROS-AGUIRRE, ILARIA GIORDANO
  • 4-SUBSTITUTED BENZOXABOROLE COMPOUNDS AND USES THEREOF
    Publication number: 20180044353
    Abstract: Substituted benzoxaboroles whose structure comprises Formula (III), wherein R3 is selected from —CH3, —CH2CH3, —CH2?CH2, —CH2CH2CH3, —CH(CH3)2, —CH2CH2?CH2, and cyclopropyl, R1 and R2 are each independently selected from H, —CH3, —CH2CH3, —CH2CH2CH3, and —CH(CH3)2; compositions containing such compounds, their use in therapy, including their use as anti-mycobacterial agents, for example in the treatment of a mycobacterial infection in a mammal, and methods for the preparation of such compounds, are provided.
    Type: Application
    Filed: February 12, 2016
    Publication date: February 15, 2018
    Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED, ANACOR PHARMACEUTICALS, INC.
    Inventors: Carlos ALEMPARTE-GALLARDO, M.R.K.(dickon) ALLEY, David BARROS-AGUIRRE, Ilaria GIORDANO, Vincent HERNANDEZ, Xianfeng LI, Jacob J. PLATTNER
  • BENZOXABOROLE COMPOUNDS AND USES THEREOF
    Publication number: 20180037595
    Abstract: Compounds whose structure comprises Formula II, or a compound whose structure comprises Formula III wherein X is selected from chloro, fluoro, bromo and iodo, R1 and R2 are each independently selected from H, —CH3, —CH2CH3, —CH2CH2CH3, or —CH(CH3)2, compositions containing them, their use in therapy, including their use as anti-mycobacterial agents, for example in the treatment of a mycobacterial infection in a mammal, and methods for the preparation of such compounds, are provided.
    Type: Application
    Filed: February 12, 2016
    Publication date: February 8, 2018
    Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED, ANACOR PHARMACEUTICALS, INC.
    Inventors: M.R.K. (dickon) ALLEY, David BARROS-AGUIRRE, Ilaria GIORDANO, Vincent HERNANDEZ, Xianfeng LI, Jacob J. PLATTNER
  • CD38 inhibitors and methods of treatment
    Patent number: 9840496
    Abstract: Compounds of Formula I and methods of treating diseases of metabolism by modulating cellular NAD+ levels through the inhibition of the CD38 enzyme, are disclosed.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: December 12, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: J. David Becherer, Rodolfo Cadilla, David Norman Deaton, Curt Haffner, Brad Richard Henke, Frank Preugschat, Christie Schulte